These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30231851)

  • 1. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
    Sommerer C; Witzke O; Lehner F; Arns W; Reinke P; Eisenberger U; Vogt B; Heller K; Jacobi J; Guba M; Stahl R; Hauser IA; Kliem V; Wüthrich RP; Mühlfeld A; Suwelack B; Duerr M; Paulus EM; Zeier M; Porstner M; Budde K;
    BMC Nephrol; 2018 Sep; 19(1):237. PubMed ID: 30231851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.
    Eisenberger U; Budde K; Lehner F; Sommerer C; Reinke P; Witzke O; Wüthrich RP; Stahl R; Heller K; Suwelack B; Mühlfeld A; Hauser IA; Nadalin S; Porstner M; Arns W;
    BMC Nephrol; 2018 Jun; 19(1):154. PubMed ID: 29954336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
    Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
    J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
    Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
    Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
    Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
    Brakemeier S; Arns W; Lehner F; Witzke O; Vonend O; Sommerer C; Mühlfeld A; Rath T; Schuhmann R; Zukunft B; Kroeger I; Porstner M; Budde K
    PLoS One; 2019; 14(9):e0222730. PubMed ID: 31536556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study.
    Holdaas H; de Fijter JW; Cruzado JM; Massari P; Nashan B; Kanellis J; Witzke O; Gutierrez-Dalmau A; Turkmen A; Wang Z; Lopez P; Bernhardt P; Kochuparampil J; van der Giet M; Murbraech K;
    Transplantation; 2017 Oct; 101(10):2612-2620. PubMed ID: 28333860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
    Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
    Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early onset of graft glomerulopathy in a patient with post-transplant diabetes mellitus after renal transplantation: a case report.
    Gregorini M; Sepe V; Pattonieri FE; Allesina A; Rampino T
    BMC Nephrol; 2018 Dec; 19(1):348. PubMed ID: 30526503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
    Budde K; Lehner F; Sommerer C; Arns W; Reinke P; Eisenberger U; Wüthrich RP; Scheidl S; May C; Paulus EM; Mühlfeld A; Wolters HH; Pressmar K; Stahl R; Witzke O;
    Am J Transplant; 2012 Jun; 12(6):1528-40. PubMed ID: 22642473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
    Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
    Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
    Gottlieb J; Neurohr C; Müller-Quernheim J; Wirtz H; Sill B; Wilkens H; Bessa V; Knosalla C; Porstner M; Capusan C; Strüber M
    Am J Transplant; 2019 Jun; 19(6):1759-1769. PubMed ID: 30615259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.